# Personalized Nutrition Market

> Personalized Nutrition Market Size, Share, Industry Trend & Analysis Research Report By Product Type (Active Measurement, Standard Measurement), By Application (Standard Supplements, Disease-based Formulations), By End User (Direct-to-Consumer, Wellness & Fitness Centres, Hospitals & Clinics), By Region (North America, Europe, Asia Pacific, Middle East & Africa, South America) - Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 13.2%
- **2025:** USD 15.35 Billion
- **2035:** USD 53.47 Billion
- **Key Players:** Nestlé Health Science, dsm-firmenich, Herbalife Ltd., Amway Corp., Viome Life Sciences, ZOE Ltd., InsideTracker, Bioniq

**Report ID:** MRFR/FnB/24046-HCR · **Pages:** 128 · **Author:** Varsha More · **Last Updated:** October 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/personalized-nutrition-market-25685

---

## Market Summary

## Personalized Nutrition Market Summary

The personalized nutrition market was valued at USD 15.35 Billion in 2025 and is forecast to reach USD 17.52 Billion in 2026, then climb to USD 53.47 Billion by 2035 at a CAGR of 13.2% over 2026–2035. Two catalysts set the pace. The U.S. FDA's March 2024 clearance of the first over-the-counter continuous [glucose](https://www.marketresearchfuture.com/reports/glucose-market-11828) monitor removed the prescription barrier to real-time metabolic feedback . Meanwhile, the NIH Common Fund's USD 170 million Nutrition for Precision Health program is building the evidence base for algorithm-driven dietary guidance across roughly 10,000 participants [3].

Behind the headline growth sits a technology swap. Generic multivitamins and static lifestyle questionnaires are giving way to regimens built from blood panels, gut-microbiome sequencing, and wearable biosensor streams, then adjusted by machine-learning models. Abbott's June 2024 clearance of two OTC biosensor systems [6] and the landmark Cell study showing that individual glycemic responses to identical meals can be predicted from personal data [13] explain why buyers now expect measurable, iterative recommendations rather than one-off product picks.

North America leads with a 38.6% revenue share in 2025, supported by OTC device access and high out-of-pocket wellness spending. Asia Pacific is the fastest-growing region at a 15.6% CAGR, driven by China's Healthy China 2030 agenda [19] and India's 2022 nutraceutical regulations [18]. Europe ranks second at USD 4.21 Billion, where harmonized health-claim rules reward clinically substantiated products [14]. Over the next decade, regional leadership in the personalized nutrition market will hinge on who converts biomarker data into reimbursable care pathways fastest.

## Key Report Takeaways

### • By Product Type

- Active Measurement is the fastest-expanding product type in the personalized nutrition market, advancing at a 14.3% CAGR through 2035 as OTC biosensors and at-home blood kits scale.
- Standard Measurement retained a 46.0% share in 2025, anchored by questionnaire-based supplement packs sold at entry price points.

### • By Application

- Standard Supplements accounted for 53.0% of 2025 revenue, reflecting broad demand for daily micronutrient packs covering energy, immunity, and cognition.
- Disease-based Formulations are projected to grow at a 13.8% CAGR as clinicians adopt nutrition-as-therapy protocols for metabolic conditions.

### • By End User

- Direct-to-Consumer channels captured 59.1% of the personalized nutrition market in 2025 on the strength of subscription models and remote sampling.
- Wellness & Fitness Centres are set to expand at a 13.4% CAGR as gyms bundle biomarker testing with training plans.
- Hospitals & Clinics generated USD 2.84 Billion in 2025, concentrated in bariatric, oncology, and [diabetes](https://www.marketresearchfuture.com/reports/diabetes-market-2966) care.

### • By Region

- North America held a 38.6% share in 2025, the largest of any region.
- Europe reached USD 4.21 Billion in 2025, led by Germany and the United Kingdom.
- Asia Pacific is forecast to post a 15.6% CAGR, the fastest regional pace.

## Market Size and Forecast (2021–2035)

Market Research Future built the historical series for the personalized nutrition market from company filings, device-clearance records, supplement-ingredient trade data, and interviews with brand owners, testing laboratories, and channel partners. Forecasts combine a bottom-up build of test volumes, subscription retention, and average revenue per user with a top-down cross-check against wellness and dietary-supplement spending. The 2024 and 2025 growth spikes reflect the first full cycle of OTC biosensor availability in the United States [6] and the arrival of companion nutrition lines for GLP-1 therapy users [8].

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| OTC biosensors and at-home biomarker testing | +2.4% | North America, Europe | Short-term (≤2 yr) | [6][25] |
| Rising cardiometabolic disease burden | +2.1% | Global | Long-term (≥4 yr) | [2] |
| AI-driven recommendation engines | +1.8% | Global | Medium-term (2–4 yr) | [13] |
| GLP-1 therapy adoption and companion nutrition | +1.7% | North America, Europe | Medium-term (2–4 yr) | [8][23] |
| Public research funding for nutrition science | +1.0% | North America, Europe | Long-term (≥4 yr) | [3] |
| Expanding regulatory acceptance of health claims | +0.9% | North America, Asia Pacific | Medium-term (2–4 yr) | [17] |

### OTC Biosensors and At-Home Biomarker Testing

The FDA's March 2024 clearance of Dexcom's Stelo, the first continuous glucose monitor sold without a prescription, opened metabolic monitoring to adults who do not use insulin . Abbott followed in June 2024 with two OTC systems [6], and Stelo reached U.S. consumers in August 2024 at USD 99 for a one-month supply [25]. Affordable, continuous data lets providers adjust formulations monthly instead of annually, lifting both retention and average order value across Active Measurement offerings.

### Rising Cardiometabolic Disease Burden

The International Diabetes Federation estimates that 589 million adults lived with diabetes in 2025, a figure projected to reach 853 million by 2050 . Separately, the World Obesity Atlas expects 51% of the global population to be overweight or obese by 2035 [2]. These numbers describe a large, motivated cohort seeking dietary tools that sit between generic advice and pharmacotherapy, supporting long-run demand for Disease-based Formulations and clinician-guided programs.

### AI-Driven Recommendation Engines

Zeevi and colleagues showed in Cell that an algorithm trained on 800 participants and 46,898 meals predicted individual glycemic responses more accurately than carbohydrate counting [13]. Commercial platforms now apply similar models to blood, microbiome, and wearable inputs at consumer scale. Each additional user improves model accuracy, creating a data flywheel that lowers the marginal cost per recommendation and widens margins for platforms with large, outcome-linked datasets.

### GLP-1 Therapy Adoption and Companion Nutrition

Novo Nordisk reported Wegovy sales above DKK 58 billion in 2024 [23], signalling millions of patients whose appetite and food intake have changed sharply. These users need protein- and fiber-dense nutrition to protect lean mass. Nestlé's May 2024 Vital Pursuit launch, priced under USD 5 per item, was built for this cohort [8]. Programs that track weight trajectory and adjust macronutrient targets are winning referrals from obesity clinics in the personalized nutrition market.

### Public Research Funding for Nutrition Science

The NIH Common Fund committed about USD 170 million over five years to Nutrition for Precision Health, enrolling roughly 10,000 participants from the All of Us program to build predictive dietary models [3]. Publicly funded datasets of this scale reduce the validation burden for commercial firms and give clinicians evidence they trust. Reference algorithms emerging from the program are expected to become licensable building blocks for smaller providers.

### Expanding Regulatory Acceptance of Health Claims

In March 2024, the FDA announced enforcement discretion for a qualified health claim linking at least two cups of yogurt per week to reduced type 2 diabetes risk . Japan's Foods with Function Claims system already permits notified, evidence-reviewed claims without product-by-product approval [17]. Clearer claim pathways let formulators communicate condition-specific benefits, strengthening the commercial case for clinically tested regimens and shortening sales cycles in pharmacy channels.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High out-of-pocket cost and limited reimbursement | −1.5% | Global | Medium-term (2–4 yr) | [25] |
| Genetic and health-data privacy concerns | −1.1% | North America, Europe | Short-term (≤2 yr) | [15][22] |
| Uneven scientific validation | −0.9% | Global | Long-term (≥4 yr) | [12] |
| Fragmented health-claim regulation | −0.7% | Europe, Asia Pacific | Medium-term (2–4 yr) | [14] |
| Subscription churn and adherence fatigue | −0.6% | North America, Europe | Short-term (≤2 yr) | [11] |

### High Out-of-Pocket Cost and Limited Reimbursement

A continuous glucose monitor priced at USD 99 per month [25] adds roughly USD 1,200 a year before supplements or coaching are counted. Most health plans still exclude consumer biomarker testing, so spending stays discretionary and skews toward higher-income households. Sizes estimates global wellness spending at USD 1.8 trillion , yet personalized offerings capture only a thin slice of it outside affluent urban cohorts.

### Genetic and Health-Data Privacy Concerns

23andMe's March 2025 Chapter 11 filing placed the genetic data of roughly 15 million customers into a court-supervised sale process [22], prompting state attorneys general to urge consumers to delete their records. The episode made data ownership a purchase criterion. In Europe, health data is a special category under GDPR, and AI-based profiling now carries added obligations under the EU AI Act [15].

### Uneven Scientific Validation

The Food4Me trial, which randomized 1607 adults from seven European nations, reported that individualized guidance improved diet quality, but that adding genetic information did not add anything to advice based on phenotypes [12]. Such results limit nutrigenomics-based marketing and nudge clinicians toward biomarker-based interventions with better outcome data. Companies without randomized data have lengthier sales cycles in the clinical channel.

### Fragmented Health-Claim Regulation

The EU's Regulation (EC) No 1924/2006 restricts marketers to a closed list of roughly 250 authorized general-function claims [14]. In the United States, the FTC's 2022 Health Products Compliance Guidance demands competent and reliable scientific evidence for every benefit statement . Divergent rules force separate label and copy strategies per country, slowing cross-border launches for mid-sized brands.

### Subscription Churn and Adherence Fatigue

Personalized programs rely on recurring orders, but the novelty wears off as the first test results come back. Herbalife mentions customer and distributor retention as a key business risk in its 2024 annual filing [11] – a concern that is not unique to digital-native firms. Churn starts to increase after the first few months for providers that don’t renew suggestions with new data, undermining the lifetime value that supports high acquisition costs.

## Opportunities

## Personalized Nutrition Market Opportunities

### Emerging Asian Markets Under New Regulatory Frameworks

India's 2022 FSSAI regulations for health supplements and nutraceuticals created a defined pathway for specialty formulations [18], and China's Healthy China 2030 plan makes nutrition improvement a national health target [19]. Both countries combine large diabetic populations with high smartphone penetration, which suits app-led, low-cost testing models. With Asia Pacific growing at a 15.6% CAGR, localized pricing and vernacular coaching are the clearest entry levers.

### Data Licensing and Platform Business Models

Food makers, insurers and medication developers are able to license insights from providers with huge, consented biomarker and outcome datasets. It’s a platform business. Retailers and clinics buy white-label testing and recommendation engines. It switches revenue from product margin to recurring software fees. Governance will pick the winners: The EU AI Act’s transparency requirements [15] benefit vendors that describe model rationale early.

### GLP-1 Companion Nutrition Programs

Patients on GLP-1 therapy need individualized protein, fiber, and micronutrient consumption, and many may eventually taper off medication and need support for weight maintenance [8][23]. Such programs that link biosensor data to dose stage and weight trajectory could evolve into a regular adjunct prescribed by obesity clinics, creating a high-retention niche within the personalized nutrition market.

### Food-as-Medicine and Employer Wellness Contracts

The FDA's December 2024 final rule redefining the "healthy" nutrient content claim  signals regulatory momentum behind diet-based prevention. Payers and self-insured employers are testing outcome-based contracts that reimburse nutrition programs tied to HbA1c or weight reductions. Disease-based Formulations, already the fastest-growing application, are best placed to capture these contracts.

### Gulf Health-Transformation Programs

Saudi Arabia's Health Sector Transformation Program under Vision 2030 prioritizes chronic-disease prevention [24], and GCC states carry some of the world's highest diabetes prevalence . Premium DTC models with Arabic-language coaching and halal-certified formulations face limited local competition, giving early entrants room to set regional pricing benchmarks.

## Future Outlook

## Personalized Nutrition Market Future Outlook

### AI Moves From Recommendation to Continuous Adjustment

Algorithms validated on meal-level glucose data [13] will evolve into closed-loop systems that adjust formulations and meal plans weekly from wearable streams. This shift makes precision nutrition an operational service rather than a one-time report. Providers will need EU AI Act-ready documentation [15] and clinical oversight protocols as regulators scrutinize automated health advice.

### Food-as-Medicine Enters Reimbursement Pathways

With 589 million adults living with diabetes , payers have strong incentives to fund diet-based interventions that delay drug escalation. The FDA's updated "healthy" claim rule  and NIH-funded predictive models [3] give insurers the evidence and labeling clarity they need. Expect reimbursement to arrive first for disease-specific programs, moving the personalized nutrition market closer to mainstream care.

### Falling Cost of Multi-Omics Testing

Illumina's NovaSeq X platform targeted whole-genome sequencing near USD 200 [20], and microbiome and metabolomic panels are following similar cost curves. Cheaper data will push multi-input testing into mid-market price tiers by the early 2030s. The competitive advantage will shift from test access to interpretation quality and proven outcomes.

### Data Governance Becomes a Competitive Moat

The 23andMe bankruptcy [22] showed consumers that health data can change hands without their consent. Brands offering verifiable deletion, local data storage, and transparent algorithm audits will win trust-sensitive buyers. Within a USD 1.8 trillion wellness economy , governance credentials will increasingly decide which platforms secure insurer and employer contracts.

## Segment Insights

## Personalized Nutrition Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Active Measurement | 14.3% CAGR (2026–2035) | OTC biosensors and at-home blood testing |
| Standard Measurement | 46.0% share (2025) | Affordable questionnaire-based packs |

Within the personalized nutrition market, Active Measurement leads revenue and also grows fastest at a 14.3% CAGR, because biosensor and blood-panel data let providers prove results and justify premium monthly pricing [25]. Standard Measurement, holding a 46.0% share, serves price-sensitive buyers through questionnaire-driven packs. Its best defence is hybrid pricing: a low-cost baseline formula with optional test upgrades, distributed through pharmacies and grocery chains to cut acquisition costs.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Standard Supplements | 53.0% share (2025) | Daily micronutrient packs for energy, immunity, cognition |
| Disease-based Formulations | 13.8% CAGR (2026–2035) | Nutrition-as-therapy protocols for metabolic disease |

Standard Supplements anchor the personalized nutrition market application mix with a 53.0% share, serving as the main gateway for first-time users. Disease-based Formulations grow faster at a 13.8% CAGR as qualified health claims  and clinician referrals legitimize therapeutic regimens for prediabetes, obesity, and cardiovascular risk. These programs demand randomized evidence but command higher prices and longer customer lifecycles, rewarding firms that invest early in trials.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Direct-to-Consumer | 59.1% share (2025) | Subscription convenience and remote sampling |
| Wellness & Fitness Centres | 13.4% CAGR (2026–2035) | Bundled biomarker testing with training plans |
| Hospitals & Clinics | USD 2.84 Billion (2025) | Bariatric, oncology, and diabetes care oversight |

Direct-to-Consumer remains the dominant end user of the personalized nutrition market at a 59.1% share, as digital brands remove clinical gatekeepers and ship kits to the door. Wellness & Fitness Centres grow fastest at a 13.4% CAGR because in-person coaching improves adherence for performance-focused members. Hospitals & Clinics, worth USD 2.84 Billion in 2025, keep a defensible niche where nutrition intersects with complex treatment in oncology and bariatric surgery.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.6% share (2025) | OTC biosensors, GLP-1 companion nutrition, DTC subscriptions |
| Europe | USD 4.21 Billion (2025) | Clinically substantiated claims, microbiome testing, pharmacy channels |
| Asia Pacific | 15.6% CAGR (2026–2035) | App-led testing, diabetes prevention, ageing populations |
| Middle East & Africa | 12.9% CAGR (2026–2035) | Vision 2030 prevention programs, premium DTC |
| South America | 5.2% share (2025) | Pharmacy-distributed kits, sports nutrition |
| Total | USD 15.35 Billion (2025) | — |

Regional dynamics in the personalized nutrition market reflect differences in device access, health-claim regulation, and out-of-pocket spending capacity. One metric is disclosed per region below.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 84.5% of regional revenue (2025) | OTC glucose biosensors and GLP-1 prescriptions |
| Canada | 12.8% CAGR (2026–2035) | Natural health product licensing and DTC uptake |
| Mexico | USD 0.39 Billion (2025) | High diabetes prevalence and pharmacy-chain kits |

The United States dominates the regional personalized nutrition market because OTC biosensors [6], high wellness spending, and a dense venture ecosystem converge there. GLP-1 adoption is reshaping demand toward protein-forward, clinically guided regimens [8]. Canada's licensing system for natural health products adds approval time but builds consumer trust, while Mexico's diabetes burden  makes pharmacy-distributed, glucose-focused kits a practical entry route.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.8% of regional revenue (2025) | Pharmacy networks and microbiome-testing start-ups |
| United Kingdom | 12.6% CAGR (2026–2035) | Large app-based cohorts and private health spending |
| France | USD 0.67 Billion (2025) | Pharmacist-led supplement advice |
| Italy | 11.2% of regional revenue (2025) | Ageing population and parapharmacy retail |
| Spain | 11.9% CAGR (2026–2035) | Sports nutrition and metabolic-health programs |
| Rest of Europe | USD 1.02 Billion (2025) | Nordic and Benelux digital-health adoption |

Germany and the United Kingdom lead European demand, supported by dense pharmacy networks and active microbiome-testing companies. The EU's closed list of health claims [14] raises the bar for marketing but rewards brands holding clinical evidence, and the Food4Me findings [12] shaped a regional preference for phenotype-based advice. France, Italy, and Spain rely heavily on pharmacists as trusted advisors, so B2B partnerships with pharmacy chains outperform pure DTC launches across Southern Europe.

### Asia Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 36.2% of regional revenue (2025) | Healthy China 2030 targets and e-commerce scale |
| Japan | USD 0.78 Billion (2025) | Foods with Function Claims and healthy ageing |
| India | 18.4% CAGR (2026–2035) | Diabetes prevalence and FSSAI nutraceutical rules |
| South Korea | 8.9% of regional revenue (2025) | Digital health apps and functional food culture |
| Australia | 13.9% CAGR (2026–2035) | Private health insurer wellness programs |
| Rest of Asia Pacific | USD 0.41 Billion (2025) | Urban middle-class growth in Southeast Asia |

China anchors regional revenue as Healthy China 2030 [19] channels public attention toward diet-related disease and e-commerce platforms lower distribution costs. Japan's Foods with Function Claims framework [17] and its ageing population support premium, evidence-backed formulations. India is the growth outlier: the 2022 FSSAI regulations [18] clarified product categories just as low-cost at-home testing and app coaching reached tier-2 cities.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| GCC | 46.3% of regional revenue (2025) | Vision 2030 prevention agendas and high incomes |
| South Africa | 12.1% CAGR (2026–2035) | Private medical schemes funding wellness benefits |
| Rest of Middle East & Africa | USD 0.21 Billion (2025) | Urban premium retail in North Africa and Levant |

GCC demand is driven by government prevention programs, including Saudi Arabia's Health Sector Transformation Program [24], and by high diabetes prevalence . Affluent consumers readily adopt premium DTC subscriptions, though halal certification and Arabic-language support are prerequisites. South Africa's private medical schemes increasingly reward members for preventive screening, creating an insurer-linked route that bypasses expensive consumer marketing.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 52.4% of regional revenue (2025) | ANVISA supplement framework and pharmacy retail |
| Argentina | 11.7% CAGR (2026–2035) | Urban fitness culture despite currency pressure |
| Rest of South America | USD 0.21 Billion (2025) | Chile and Colombia private-clinic demand |

Brazil holds the majority of regional revenue, helped by ANVISA's 2018 food supplement framework, which standardized permitted ingredients and claims, and by large pharmacy chains willing to stock entry-level testing kits. Argentina's growth is real but volatile, as inflation squeezes discretionary spending. Across the region, partnerships with gyms and private clinics outperform standalone DTC models because consumer trust in remote sampling is still developing.

## Competitive Benchmarking

## Competitive Benchmarking

The personalized nutrition market is moderately concentrated, with an estimated HHI of 700–850 and the top five players holding roughly 24–32% of revenue. Diversified food and ingredient groups such as Nestlé [9] and dsm-firmenich [10] compete alongside direct-selling giants and venture-backed testing platforms. Fragmentation is highest in DTC testing, where dozens of regional start-ups compete on price and data features, while clinical channels favor established brands with trial evidence.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Nestlé Health Science | ~6–9% | Persona Nutrition vitamin packs, Vital Pursuit GLP-1 line, medical nutrition | Breadth across DTC and clinical channels |
| dsm-firmenich | ~5–8% | Personalized premixes, ingredient platforms, B2B formulation services | Ingredient enabler for brand partners |
| Herbalife Ltd. | ~4–7% | Distributor-led nutrition programs, digital coaching tools | Direct-selling scale with community coaching |
| Amway Corp. | ~3–6% | Nutrilite personalized supplement packs, wellness assessments | Direct-selling reach across Asia Pacific |
| Viome Life Sciences | ~2–4% | Gut microbiome and RNA testing with tailored supplements | Data-led DTC platform |
| ZOE Ltd. | ~2–4% | At-home gut and blood-fat testing, nutrition app | Science-led brand built on large cohort studies |
| InsideTracker | ~1–3% | Blood biomarker analysis, wearable integration | Performance and longevity positioning |
| Bioniq | ~1–2% | Blood-test-based supplement granules reformulated monthly | Premium subscription model |
| Nourished | ~1–2% | 3D-printed personalized gummy stacks | Format innovation for DTC buyers |
| GenoPalate | ~0.5–1.5% | Genetic-based nutrition reports and meal guidance | Low-cost entry for genotype-curious consumers |

## Recent News & Developments

## Recent News & Developments

The developments below shaped regulatory and competitive conditions in the personalized nutrition market between 2023 and 2025.

- dsm-firmenich (May 2023): DSM and Firmenich completed their merger, creating a combined nutrition and ingredients group with expanded capacity for personalized premix supply to brand partners. [10]
- U.S. FDA (March 2024): Cleared Dexcom's Stelo as the first over-the-counter continuous glucose monitor, opening real-time metabolic data to non-insulin users.
- U.S. FDA (March 2024): Announced enforcement discretion for a qualified health claim linking yogurt intake to reduced type 2 diabetes risk, a precedent for condition-specific food claims.
- Nestlé Health Science (May 2024): Unveiled Vital Pursuit, a frozen meal line designed for GLP-1 medication users, validating companion nutrition as a mainstream category. [8]
- Abbott (June 2024): Received FDA clearance for two OTC biosensor systems, Lingo and Libre Rio, adding a second major supplier to consumer glucose monitoring. [6]
- Dexcom (August 2024): Made Stelo available to U.S. consumers at USD 99 per month, setting an early price benchmark for OTC metabolic monitoring. [25]
- U.S. FDA (December 2024): Finalized the updated definition of the "healthy" nutrient content claim, aligning labeling with current dietary guidance.
- 23andMe (March 2025): Filed for Chapter 11 protection, putting customer genetic data into a sale process and intensifying scrutiny of consumer health-data practices. [22]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The personalized nutrition market covers Active Measurement and Standard Measurement offerings used in Standard Supplements and Disease-based Formulations, delivered through Direct-to-Consumer, Wellness & Fitness Centres, and Hospitals & Clinics channels. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 15.35 Billion |
| Market Size in 2035 | USD 53.47 Billion |
| CAGR | 13.2% (2026–2035) |
| Fastest Growing Segments | Active Measurement (14.3% CAGR); Disease-based Formulations (13.8% CAGR); Wellness & Fitness Centres (13.4% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Nestlé Health Science, dsm-firmenich, Herbalife Ltd., Amway Corp., Viome Life Sciences, ZOE Ltd., InsideTracker, Bioniq, Nourished, GenoPalate |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should investors evaluate before backing a start-up in the personalized nutrition market?**
A: Prioritize retention beyond twelve months and margin on refill orders over test-kit volume. Start-ups owning proprietary outcome data attract stronger acquirer interest than formulation-only brands [10].

**Q: How do OTC glucose biosensors compare with genetic tests for personalization?**
A: Biosensors capture day-to-day responses to specific meals, while genetic tests describe fixed predispositions. Glucose data therefore supports frequent regimen changes, whereas genotype results mainly guide one-time baseline choices [13].

**Q: Which regulatory nuance matters most for brands entering the personalized nutrition market in Japan?**
A: Foods with Function Claims allows notified claims backed by systematic reviews rather than pre-approval. After the 2024 red-yeast-rice safety incident, the Consumer Affairs Agency tightened post-market reporting, raising documentation expectations [17].

**Q: How should employers procure personalized nutrition programs for staff?**
A: Employers should negotiate outcome-linked fees tied to HbA1c or weight changes and require that individual data stays outside employer access. This structure keeps vendors in the personalized nutrition market accountable for measurable results [21].

**Q: What integration challenges do hospitals face when joining the personalized nutrition market?**
A: Most consumer platforms export PDF reports rather than structured data compatible with electronic health records. Clinics also need dietitian time for interpretation, which is rarely reimbursed outside defined medical nutrition therapy [3].

**Q: How is the GLP-1 drug wave changing product formulation priorities?**
A: Formulators are raising protein density and adding fiber and micronutrients to offset reduced intake and lean-mass loss. Portion-controlled, high-protein formats now take shelf space once held by general meal replacements [8].

**Q: Which emerging use case could open new revenue streams in the personalized nutrition market?**
A: Healthy-ageing programs for adults over 60, pairing muscle-health biomarkers with protein and vitamin D tailoring, remain underpenetrated. Ageing demographics in Japan and South Korea make this cohort a strong subscription opportunity in the personalized nutrition market [17].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/personalized-nutrition-market-25685*